Breaking Down Jazz Pharmaceuticals: 15 Analysts Share Their Views
Portfolio Pulse from Benzinga Insights
15 analysts have recently shared their views on Jazz Pharmaceuticals (NASDAQ:JAZZ), with a mix of bullish and somewhat bullish ratings dominating. The average 12-month price target is $196.6, a slight decrease from the previous average. Analysts have adjusted their ratings and price targets based on market conditions and company performance. Jazz Pharmaceuticals, an Ireland-based biopharmaceutical company, focuses on treatments for sleeping disorders and oncology. Despite a market capitalization below industry benchmarks and an ROE below industry averages, the company has shown strong revenue growth and net margin.
April 10, 2024 | 2:01 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
15 analysts have provided mixed ratings for Jazz Pharmaceuticals, with a slight decrease in the average 12-month price target to $196.6. The company's focus on sleeping disorders and oncology treatments, along with strong revenue growth and net margin, are key highlights.
The mixed analyst ratings with a slight decrease in the average price target suggest a neutral short-term impact on JAZZ's stock price. The company's strong financial performance, particularly in revenue growth and net margin, alongside its focus on critical healthcare areas, supports a stable outlook. However, the varied analyst perspectives and the slight decrease in the price target introduce uncertainty, leading to a neutral score.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100